

October 27, 2004

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN (QQ-105)	BELATACEPT
PRONUNCIATION	bel a ta' sept
THERAPEUTIC CLAIMS	prevention of allograft rejection in recipients of solid organ transplants; prevention of graft-vs.-host disease following bone marrow transplantation; treatment of autoimmune diseases and conditions such as rheumatoid arthritis and Type 1 diabetes

CHEMICAL NAMES

- 1) CTLA-4 (antigen) [29-tyrosine,104-glutamic acid] (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment), bimol. (120→120')-disulfide
- 2) [Tyr²⁹,Glu¹⁰⁴,Gln¹²⁵,Ser¹³⁰,Ser¹³⁶,Ser¹³⁹,Ser¹⁴⁸](CTLA-4 (antigen)-[3-126]-peptide (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1-[233 C-terminal residues of the heavy chain]-peptide (human monoclonal Fc domain-containing fragment)) bimolecular (120→120')-disulfide

STRUCTURAL FORMULA

(see page 2)

MOLECULAR FORMULA	C ₃₅₀₈ H ₅₄₄₀ N ₉₂₂ O ₁₀₉₆ S ₃₂
MOLECULAR WEIGHT	91.5 kDa
TRADEMARK	Unknown as yet
MANUFACTURER	Bristol-Myers Squibb
CODE DESIGNATION	BMS-224818
<u>CAS</u> REGISTRY NUMBER	706808-37-9
WHO NUMBER	8627

SVF

MHVAQPAVVL	ASSRGIASFV
CEYASPGKYT	EVRVTVLRQA
DSQVTEVCAA	TYMMGNELTF
LDDSICTGTS	SGNQVNLTIQ
GLRAMDTGLY	ICKVELMYPP
PYYEGIGNGT	QIYVIDPEPC
PDSDQEPKSS	DKTHTSPPSP
APELLGGSSV	FLFPPKPKDT
LMISRTPEVT	CVVVDVSHED
PEVKFNWYVD	GVEVHNAKTK
PREEQYNSTY	RVVSVLTVLH
QDWLNGKEYK	CKVSNKALPA
PIEKTISKAK	GQPREPQVYT
LPPSRDELTK	NQVSLTCLVK
GFYPSDIAVE	WESNGQPENN
YKTTTPVLDS	DGSFFLYSKL
TVDKSRWQQG	NVFSCSVMHE
ALHNHYTQKS	LSLSPGK

* glycosylation sites